Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Sartorius AG    SRT   DE0007165607

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius : Resolutions of the Annual Shareholders' Meeting of Sartorius AG

06/26/2020 | 07:34am EST

Press Release

Göttingen, June 26, 2020

Resolutions of the Annual Shareholders' Meeting of Sartorius AG

At today's virtual Annual General Shareholders' Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority. They passed the resolution to pay dividends of 0.36 euros per preference share (previous year: 0.62 euros) and 0.35 euros per ordinary share (previous year: 0.61 euros). The total amount disbursed will be 24.3 million euros after 42.1 million euros in the previous year. The dividend will be paid out on July 1, 2020.

In addition, shareholders elected Prof. David Ebsworth as a shareholder representative to the Supervisory Board. Prof. Ebsworth has already been a member of the board since January 2020. He was appointed by court order after Dr. Guido Oelkers resigned from his position on the Supervisory Board of Sartorius AG at the end of 2019. Prof. Ebsworth has extensive expertise and many years of experience in managing and advising pharmaceutical and biopharmaceutical companies. For more than 19 years, he worked for Bayer, where he was most recently responsible for the global Pharmaceuticals Division. From 2002 onwards, he worked in management at various biopharmaceutical companies, including as CEO of Vifor Pharma and as Chairman of the Corporate Executive Committee of Galenica Group. Currently, he is the non-executive chairman of the Board of Directors of Verona Pharma.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language earnings release. Sartorius shall not assume any liability for the correctness of this translation. The original German earnings release is the legally binding version.

Presentation and further information on the 2020 Annual General Shareholders' Meeting https://www.sartorius.com/shareholders-meeting

Current image files https://www.sartorius.com/en/company/newsroom/downloads-publications

Financial calendar

July 21, 2020

Publication of first-half figures (January to June 2020)

October 20, 2020

Publication of nine-month figures (January to September 2020)

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services

Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Petra Kirchhoff

Head of Corporate Communications and Investor Relations +49 (0)551.308.1686 petra.kirchhoff@sartorius.com

sartorius.com

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

Disclaimer

Sartorius AG published this content on 26 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 June 2020 11:33:02 UTC


© Publicnow 2020
All news about SARTORIUS AG
08:52aSARTORIUS : Partners With RoosterBio to Advance Cell and Gene Therapy Manufactur..
PU
01/06SARTORIUS : to acquire Novasep's chromatography process equipment...
PU
01/05SARTORIUS STEDIM BIOTECH SA : Bilan SEMESTRIEL S2 -2-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -3-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -2-
DJ
01/04SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
MD
01/04SARTORIUS STEDIM BIOTECH SA : Declaration relative to the number of shares and v..
DJ
2020SARTORIUS : and Evotec Partner With Start-up Curexsys on IPSC-Based...
PU
2020PRESS RELEASE : Evotec and sartorius partner with -2-
DJ
2020SARTORIUS : pays employees a coronavirus bonus
PU
More news
Financials
Sales 2020 2 305 M 2 785 M 2 785 M
Net income 2020 233 M 282 M 282 M
Net Debt 2020 1 759 M 2 125 M 2 125 M
P/E ratio 2020 115x
Yield 2020 0,23%
Capitalization 24 626 M 29 774 M 29 749 M
EV / Sales 2020 11,4x
EV / Sales 2021 9,60x
Nbr of Employees 10 008
Free-Float 46,8%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 246,58 €
Last Close Price 347,00 €
Spread / Highest target 1,15%
Spread / Average Target -28,9%
Spread / Lowest Target -80,2%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chief Executive Officer
Lothar Kappich Chairman-Supervisory Board
Volker Niebel Head-Production, Procurement & Business Operations
Rainer Lehmann Chief Financial Officer
Oscar-Werner Reif Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG0.58%29 870
REVENIO GROUP OYJ0.40%1 627
ALPHATEC HOLDINGS, INC.0.76%1 147
CELLAVISION AB (PUBL)2.41%902
VAREX IMAGING CORPORATION12.65%736
OXFORD IMMUNOTEC GLOBAL PLC25.68%570